rewrite this title and make it good for SEODiaSorin shares plunge 17% as 2026 margin outlook shadows FY25 earnings By Investing.com

Investing.com — reported a 20% fall in full-year net profit on Friday, sending shares in the Italian diagnostics group down by 17% on Monday after the company guided for flat-to-lower margins in 2026.

Monday’s decline took the stock to its lowest in the 10-year price history, below the €58.36 trough recorded in 2025, and extended losses from the stock’s all-time high of €209.40 reached in May 2020 to 74%.

Net profit fell to €150 million from €187 million in 2024, weighed down by a €20 million charge to close its Shanghai manufacturing plant and higher taxes, including non-recurring levies on dividends distributed by subsidiaries.

Revenue rose 1% to €1.20 billion, or 4% at constant exchange rates, with foreign exchange headwinds costing the group €34 million. Excluding COVID-related sales, revenue grew 5% at constant rates, in line with full-year guidance.

Adjusted EBITDA held flat at €394 million with a 33% margin, while free cash flow fell to €209 million from €241 million.

Chief executive Carlo Rosa flagged that molecular diagnostics were flat year-on-year, primarily because the flu season in 2025 was very weak.

Immunodiagnostics ex-COVID, the group’s largest segment at 69% of revenue, grew 7% at constant rates to €821 million, driven by specialty CLIA test sales in the United States. Excluding China, the segment grew 8% at constant rates.

Licensed Technologies revenue was flat at constant rates at €165 million, as strong diagnostics customers were offset by a decline in Life Science sales following cuts to NIH funding in the United States.

The Board proposed a dividend of €1.30 per share, up 8.3% from 2024, and authorised a share buyback programme of up to €250 million covering a maximum of 4.5 million shares, or 8.04% of share capital. The company had repurchased 1.84 million treasury shares as of March 19.

DiaSorin said it would close its Shanghai plant by end-2026, generating annual cost savings of approximately €6 million with a cash payback period of less than one year.

Total restructuring charges are estimated at up to €22 million, of which approximately €20 million were recognised in 2025.

For 2026, DiaSorin guided for revenue growth of 5% to 6% at constant exchange rates and an adjusted EBITDA margin of 32% to 33%. The company noted the guidance excluded any impact from the Middle East conflict, which it said could affect regional sales and supply chains.

The group’s net financial debt stood at €580 million at December 31, down from €618 million a year earlier.